Efficacy and safety of once-weekly semaglutide 2.4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial
Most of the research thats been published, including one of these two recent studies, does continue to support the idea that there is an increased risk of NAION occurring in patients that are taking these GLP-1 medications, he continued
Soon after the session, most patients can return to their regular activities
Sesame founder and president Michael Botta, M.D., said the FDA declaration won't have an impact on Sesame's business
That is why it is also known as a dual GLP-1/GIP receptor agonist
It is part of a class of drugs called GLP-1 receptor agonists, which mimic the action of a hormone in the body that helps regulate blood sugar levels